Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats

Virology Journal

Volumn 6, Issue , 2009, Pages

  El Awady, Mostafa K ^a   Tabll, Ashraf A ^a   El Abd, Yasmine S ^a   Yousif, Hassan ^a   Hegab, Mohsen ^a   Reda, Mohamed ^a   El Shenawy, Reem ^a   Moustafa, Rehab I ^a   Degheidy, Nabila ^a   El Din, Noha G Bader ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E2; P36 PEPTIDE; P37 PEPTIDE; P38 PEPTIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; GLYCOPROTEIN E2, HEPATITIS C VIRUS; HEPATITIS C ANTIBODY; SUBUNIT VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG RESPONSE; GENOTYPE; GOAT; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN VARIABLE REGION; MAJOR CLINICAL STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; ANIMAL; IMMUNOLOGY; MOLECULAR GENETICS; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; SEQUENCE ALIGNMENT; SERODIAGNOSIS;

ANIMALIA; CAPRA HIRCUS; HEPATITIS C VIRUS;

AMINO ACID SEQUENCE; ANIMALS; CELL PROLIFERATION; CONSERVED SEQUENCE; GOATS; HEPACIVIRUS; HEPATITIS C ANTIBODIES; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; SEQUENCE ALIGNMENT; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS;

EID: 67649973482     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-66     Document Type: Article

References (47)

1. Hepatitis C virus infection. GM Lauer BD Walker, N Engl J Med 2001 345 41 52 10.1056/NEJM200107053450107 11439948
2. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. C Frank MK Mohamed GT Strickland D Lavanchy RR Arthur LS Magder T El Khoby Y Abdel-Wahab ES Aly Ohn W Anwar I Sallam, Lancet 2000 355 887 891 10.1016/S0140-6736(99)06527-7 10752705
3. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. GT Strickland, Hepatology 2006 43 915 922 10.1002/hep.21173 16628669
4. Epidemiology of hepatitis C. MJ Alter, Hepatology 1997 26 3 suppl 1 62S 65 10.1002/hep.510260711 9305666
5. Discovery of non-A, non-B hepatitis and identification of its etiology. H Alter, Am J Med 1999 107 16S 20 10.1016/S0002-9343(99)00375-7 10653450
6. Estimating progression to cirrhosis in chronic hepatitis C virus infection. AJ Freeman GJ Dore MG Law M Thorpe J Von Overbeck AR Lloyd G Marinos JM Kaldor, Hepatology 2001 34 809 816 10.1053/jhep.2001.27831 11584380
7. The natural history of hepatitis C virus infection: host, viral, and environmental factors. DL Thomas J Astemborski RM Rai FA Anania M Schaeffer N Galai K Nolt KE Nelson SA Strathdee L Johnson O Laeyendecker J Boitnott LE Wilson D Vlahov, JAMA 2000 284 450 56 10.1001/jama.284.4.450 10904508
8. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. E Kenny-Walsh, N Engl J Med 1999 340 1228 1233 10.1056/NEJM199904223401602 10210705
9. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany - a 25-year multicenter study. M Wiese K Grungreiff W Guthoff M Lafrenz U Oesen H Porst, J Hepatol 2005 43 590 598 10.1016/j.jhep.2005.04.007 16237783
10. Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s. P Ferenci S Ferenci C Datz I Rezman W Oberaigner R Strauss, J Hepatol 2007 47 31 36 10.1016/j.jhep.2007.01.023 17335929
11. Treating viral hepatitis C: efficacy, side effects, and complications. MP Manns H Wedemeyer M Cornberg, Gut 2006 55 1350 1359 10.1136/gut.2005.076646 16905701
12. HCV-HIV coinfection: simple messages from a complex disease. P Klenerman A Kim, PLoS Med 2007 4 e240 17927445 10.1371/journal.pmed.0040240
13. Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? I Pachiadakis G Pollara BM Chain NV Naoumov, Lancet Infect Dis 2005 5 5 296 304 10.1016/S1473-3099(05)70114-6 15854885
14. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. S Phogat RT Wyatt GB Karlsson, J Intern Med 2007 262 26 43 17598813 10.1111/j.1365-2796.2007.01820.x
15. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. JM Heile YL Fong D Rosa K Berger G Saletti S Campagnoli G Bensi S Capo S Coates K Crawford C Dong M Wininger G Baker L Cousens D Chien P Ng P Archangel G Grandi M Houghton S Abrignani, J Virol 2000 74 6885 6892 10888628 10.1128/JVI.74.15.6885-6892.2000
16. Multimeric HCV E2 protein obtained from Pichia pastoris cells induces a strong immune response in mice. G Martínez-Donato Y Capdesũer N Acosta-Rivero A Rodríguez J Morales-Grillo E Martínez M González JC Alvarez-Obregon S Duẽas-Carrera, Mol Biotechnol 2007 35 225 235 10.1007/BF02686008 17652786 (Pubitemid 47233921)
17. Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. JD Abraham N Himoudi F Kien JL Berland A Codran B Bartosch, Vaccine 2004 22 3917 3928 10.1016/j.vaccine.2004.04.005 15364440
18. Evaluating replication defective vesicular stomatitis virus as a vaccine vehicle. AM Majid H Ezelle S Shah GN Barber, J Virol 2006 80 6993 7008 16809305 10.1128/JVI.00365-06
19. DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpGoptimized vectors in mice. X Ma X Forns R Gutierrez IK Mushahwar T Wu PJ Payette J Bukh RH Purcell HL Davis, Vaccine 2002 20 3263 3271 10.1016/S0264-410X(02)00304-3 12213395
20. Vaccine development for hepatitis C. M Lechmann TJ Liang, Semin Liver Dis 2000 20 211 226 10.1055/s-2000-9947 10946425 (Pubitemid 30618717)
21. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. A Fournillier E Depla P Karayiannis O Vidalin G Maertens C Trépo G Inchauspé J Virol 1999 73 7497 7504 10438839 (Pubitemid 29383233)
22. Vaccination of chimpanzees against infection by the hepatitis C virus. QL Choo G Kuo R Ralston A Weiner D Chien G Van Nest J Han K Berger K Thudium C Kuo, Proc Natl Acad Sci USA 1994 91 1294 1298 7509068 10.1073/pnas.91.4.1294 (Pubitemid 24058997)
23. Epitope mapping of the NS4 and NS5 gene products of hepatitis C virus and the use of a chimeric NS4-NS5 synthetic peptide for serodiagnosis. C Rosa S Osborne F Garetto S Griva A Rivella G Calabresi R Guaschino F Bonelli, J Virol Methods 1995 55 219 232 10.1016/0166-0934(95)00060-8 8537460
24. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. JW Youn SH Park D Lavillette FL Cosset SH Yang CG Lee HT Jin CM Kim MT Shata DH Lee W Pfahler AM Prince YC Sung, Hepatology 2005 42 1429 1436 10.1002/hep.20934 16317673
25. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. M Puig ME Major K Mihalik SM Feinstone, Vaccine 2007 22 991 1000 10.1016/j.vaccine.2003.09.010
26. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. JM Christie CJ Healey J Watson VS Wong M Duddridge N Snowden WM Rosenberg KA Fleming H Chapel RW Chapman, Clin Exp Immunol 1997 110 4 8 9353141 10.1111/j.1365-2249.1997.508-ce1412.x (Pubitemid 27428507)
27. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. HM Chapel JM Christie V Peach RW Chapman, Clin Immunol 2001 99 320 324 10.1006/clim.2001.5036 11358426
28. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. JA McKeating LQ Zhang C Logvinoff M Flint J Zhang J Yu D Butera DD Ho LB Dustin CM Rice P Balfe, J Virology 2004 78 8496 8505 15280458 10.1128/JVI.78.16.8496-8505.2004
29. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. K Krawczynski MJ Alter DL Tankersley M Beach BH Robertson S Lambert G Kuo JE Spelbring E Meeks S Sinha DA Carson, J Infect Dis 1996 173 822 828 8603959 (Pubitemid 26176003)
30. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. CS Klade H Wedemeyer T Berg H Hinrichsen G Cholewinska S Zeuzem H Blum M Buschle S Jelovcan V Buerger E Tauber J Frisch MP Manns, Gastroenterology 2008 134 5 1385 1395 10.1053/j.gastro.2008.02.058 18471515
31. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. C Firbas B Jilma E Tauber V Buerger S Jelovcan K Lingnau M Buschle J Frisch CS Klade, Vaccine 2006 15;24 20 4343 4353 10.1016/j.vaccine.2006.03.009
32. Synthetic peptide-based immunoassay as a supplemental test for HCV infection. MK El Awady MA El-Demellawy SB Khalil D Galal SA Goueli, Clin Chim Acta 2002 325 1-2 39 46 10.1016/S0009-8981(02)00245-0 12367764
33. A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid. MM McKinney A Parkinson, J Immunol Methods 1987 11;96 2 271 278 10.1016/0022-1759(87)90324-3
34. Optimal preparation of rhesus macaque blood for cytokine flow cytometric analysis. LE Nomura ED deHaro LN Martin HT Maecker, Cytometry A 2003 53 1 28 38 10.1002/cyto.a.10038 12701130 (Pubitemid 37521501)
35. Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro. MK El-Awady AA Tabll K Atef SS Yousef MH Omran Y El-Abd NG Bader-Eldin AM Salem SF Zohny WT El-Garf, World J Gastroenterol 2006 28; 12 16 2530 2535
36. Cross-genotype immunity to hepatitis C virus. RE Lanford B Guerra D Chavez C Bigger KM Brasky XH Wang SC Ray DL Thomas, J Virol 2004 78 3 1575 1581 14722311 10.1128/JVI.78.3.1575-1581.2004
37. Prospects for a vaccine against the hepatitis C virus. M Houghton S Abrignani, Nature 2005 18; 436 7053 961 966 10.1038/nature04081
38. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. P Simmonds J Bukh C Combet G Deléage N Enomoto S Feinstone P Halfon G Inchauspé C Kuiken G Maertens M Mizokami DG Murphy H Okamoto JM Pawlotsky F Penin E Sablon IT Shin LJ Stuyver HJ Thiel S Viazov AJ Weiner A Widell, Hepatology 2005 42 962 973 10.1002/hep.20819 16149085
39. The Los Alamos hepatitis C sequence database. C Kuiken K Yusim L Boykin R Richardson, Bioinformatics 2005 21 379 384 10.1093/bioinformatics/bth485 15377502
40. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. T von Hahn JC Yoon H Alter CM Rice B Rehermann P Balfe JA McKeating, Gastroenterology 2007 132 2 667 678 10.1053/j.gastro.2006.12.008 17258731
41. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Z Stamataki S Coates MJ Evans M Wininger K Crawford C Dong YL Fong D Chien S Abrignani P Balfe CM Rice JA McKeating M Houghton, Vaccine 2007 25 45 7773 7784 10.1016/j.vaccine.2007.08.053 17919789
42. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. P Zhang CG Wu K Mihalik ML Virata-Theimer MY Yu HJ Alter SM Feinstone, Proc Natl Acad Sci USA 2007 15;104 20 8449 8454 10.1073/pnas.0703039104
43. Immunizations with chimeric hepatitis B virus-like particles to induce potential antihepatitis C virus neutralizing antibodies. PT Vietheer I Boo HE Drummer HJ Netter, Antivir Ther 2007 12 477 487 17668556 (Pubitemid 47041146)
44. A self-adjuvanting multiepitope immunogen that induces a broadly cross reactive antibody to hepatitis C virus. J Torresi OM Stock AE Fischer L Grollo H Drummer I Boo W Zeng L Earnest-Silveira DC Jackson, Hepatology 2007 45 911 920 10.1002/hep.21538 17393515
45. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. DJ Schofield B Bartosch YK Shimizu T Allander HJ Alter SU Emerson FL Cosset RH Purcell, Hepatology 2005 42 1055 1062 10.1002/hep.20906 16250048
46. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. R Eren D Landstein D Terkieltaub O Nussbaum A Zauberman J Ben-Porath J Gopher R Buchnick R Kovjazin Z Rosenthal-Galili S Aviel E Ilan Y Shoshany L Neville T Waisman O Ben-Moshe A Kischitsky SK Foung ZY Keck O Pappo A Eid O Jurim G Zamir E Galun S Dagan, J Virol 2006 80 2654 2664 16501075 10.1128/JVI.80.6.2654-2664.2006
47. A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses. LX Zhu J Liu Y Ye YH Xie YY Kong GD Li Y Wang, World J Gastroenterol 2004 10 17 2488 2492 15300890 (Pubitemid 39206765)